Related Experiment Video
Updated: Apr 20, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
An epigenetic therapy for diffuse intrinsic pontine gliomas
Vijay Ramaswamy1, Marc Remke1, Michael D Taylor1
1Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract:
Diffuse intrinsic pontine glioma is a uniformly lethal malignant tumor of infancy with no effective therapies. A new study reveals that inhibition of JMJD3 has robust antitumor activity in diffuse intrinsic pontine glioma xenografts.
Insights
A new study shows that inhibiting JMJD3 effectively combats diffuse intrinsic pontine glioma, a deadly infant cancer. This finding offers hope for new diffuse intrinsic pontine glioma therapies targeting JMJD3.
Area of Science:
- Oncology
- Pediatric Cancer Research
- Molecular Biology
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and uniformly lethal brain tumor affecting infants.
- Current therapeutic options for DIPG are ineffective, highlighting an urgent need for novel treatment strategies.
Purpose of the Study:
- To investigate the therapeutic potential of targeting JMJD3 in diffuse intrinsic pontine glioma.
Main Methods:
- The study utilized diffuse intrinsic pontine glioma xenograft models.
- Inhibition of JMJD3 was employed as a therapeutic strategy.
Main Results:
- Targeting JMJD3 demonstrated significant antitumor activity in diffuse intrinsic pontine glioma xenografts.
- This inhibition effectively suppressed tumor growth in preclinical models.
Conclusions:
- Inhibition of JMJD3 presents a promising therapeutic avenue for treating diffuse intrinsic pontine glioma.
- Further research into JMJD3 inhibitors could lead to effective treatments for this devastating pediatric cancer.
